Pink SheetThe Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai
ScripThe pharmaceutical industry in Europe has criticized the Council of the EU’s adoption of a package of legislative reforms for medicines, claiming that the continent’s innovation-unfriendly environment
ScripVigil Neuroscience’s TREM2 agonist iluzanebart failed in a Phase II study for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and deadly neurod
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D